NTRK1 and cancer: Sorafenib primarily targets serine/threonine kinases, vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor beta (PGFRβ), kit, fms-like tyrosine kinase-3 (FLT3), proto-oncogene ret (RET), and other receptor tyrosine kinases, which subsequently inhibit cancer cell proliferation and angiogenesis through mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (ERK) [53].